Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study: Erratum
Guardado en:
Formato: | article |
---|---|
Lenguaje: | EN |
Publicado: |
Wolters Kluwer
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9ab25923987948a28b8e68386aa0db67 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A single‐center, open‐label, randomized cross‐over study to evaluate the pharmacokinetics and bioavailability of once‐daily prolonged‐release formulations of tacrolimus in de novo liver transplant recipients
por: Uta Herden, et al.
Publicado: (2021) -
Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients
por: Locke JE, et al.
Publicado: (2011) -
Challenges of Diagnosing Severe Ehrlichiosis in Orthotopic Liver Transplant Recipients
por: Melissa Parkinson, et al.
Publicado: (2021) -
Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
por: Christopher J. Mowry, MD, et al.
Publicado: (2021) -
Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients
por: Cheng F, et al.
Publicado: (2021)